Division of Cardiovascular Medicine

Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.

A mysterious inflammatory syndrome linked to COVID-19 infection and first identified in children also occurs in adults, Vanderbilt researchers report.

Andrew DeFilippis, MD, has joined Vanderbilt University Medical Center from the University of Louisville School of Medicine. He began seeing patients in September 2020.

Researchers at Vanderbilt University Medical Center (VUMC) have received a four-year, $6.2-million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop a novel panel of biomarkers to improve the diagnosis of acute heart failure (AHF).

A novel hormone deficiency may exist in humans, Vanderbilt investigators have discovered. In an analysis of two decades worth of electronic health records, the researchers found that some patients have unexpectedly low levels of natriuretic peptide hormone in clinical situations that should cause high levels of the hormone.

Thanks to major funding from the National Institutes of Health (NIH), researchers at Vanderbilt University Medical Center have made major inroads in understanding how high-density lipoprotein (HDL), commonly known as good cholesterol, in some cases may actually contribute to the development of atherosclerosis.